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Background. Fibrosis, the replacement of functional tissue with excessive fibrous tissue, can occur in all the main tissues and
organ systems, resulting in various pathological disorders. Idiopathic Pulmonary Fibrosis is a prototype fibrotic disease
involving abnormal wound healing in response to multiple sites of ongoing alveolar epithelial injury. Methodology/Principal
Findings. To decipher the role of TNF and TNF-mediated inflammation in the development of fibrosis, we have utilized the
bleomycin-induced animal model of Pulmonary Fibrosis and a series of genetically modified mice lacking components of TNF
signaling. Transmembrane TNF expression is shown to be sufficient to elicit an inflammatory response, but inadequate for the
transition to the fibrotic phase of the disease. Soluble TNF expression is shown to be crucial for lymphocyte recruitment,
a prerequisite for TGF-b1 expression and the development of fibrotic lesions. Moreover, through a series of bone marrow
transfers, the necessary TNF expression is shown to originate from the non-hematopoietic compartment further localized in
apoptosing epithelial cells. Conclusions. These results suggest a primary detrimental role of soluble TNF in the pathologic
cascade, separating it from the beneficial role of transmembrane TNF, and indicate the importance of assessing the efficacy of
soluble TNF antagonists in the treatment of Idiopathic Pulmonary Fibrosis.
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INTRODUCTION
Fibroproliferative diseases are among the leading causes of
morbidity and mortality worldwide. Fibrosis, the replacement of
functional tissue with excessive fibrous tissue, can occur in all the
main tissues and organ systems resulting in various disorders
including cardiac, cerebral and peripheral vascular disease, liver
cirrhosis, progressive kidney disease and a number of interstitial
lung diseases such as idiopathic pulmonary fibrosis (IPF). Despite
their obvious etiological and clinical distinctions, most of these
fibrotic diseases have in common a persistent inflammatory
stimulus that sustains and/or stimulates the production of growth
factors and fibrogenic cytokines, which together stimulate the
deposition of connective-tissue elements that progressively remodel
and destroy normal tissue architecture.
IPF (also known as cryptogenic fibrosing alveolitis) is a chronic,
interstitial, fibrotic lung disease, with a prevalence of 7–10:100000
(increasing with age) and a mean survival of 3–4 years (decreasing
with age). Clinically, IPF is characterized by progressive, exertional
dyspnea and nonproductive cough, worsening of pulmonary
function and radiographically evident interstitial infiltrates (honey-
combing). Histologically, IPF is associated with the appearance of
Usual Interstitial Pneumonitis (UIP), which is characterized by
patchy subpleural and/or paraseptal interstitial fibrosis alternating
with areas of mild inflammation and normal lung. The hallmark of
IPF/UIP is the distinctive presence of fibroblastic foci and exuberant
Extracellular Matrix (ECM) deposition, leading to thickening of
alveolar septa and the collapse of normal lung architecture. Due to
the lack of a more effective alternative, the fundamental therapeutic
approach has been use of corticosteroids, alone or in combination
with other immunosuppressive agents; however, this has little impact
on long-term survival [1,2].
Although the etiology and pathogenesis of IPF remain poorly
understood, a number of conditions and risk factors are weakly
associated with the disease: cigarette smoking, occupational/
environmental factors, latent viral infections, as well as age/
gender/genetic predisposition. The occurrence of pulmonary
fibrosis (with a UIP histological pattern) as a side effect in humans
receiving bleomycin (BLM) for cancer chemotherapy led to the
development of a BLM-induced animal model of pulmonary
fibrosis (BLM/PF). Despite the intrinsic limitations and the
evolutionary distance, the BLM/PF animal model shares many
clinical features with the human disease, and therefore provides
valuable insights into the pathogenetic mechanisms that govern
disease activation and perpetuation. Utilization of this model, as
well as site-specific and/or temporal overexpression or ablation of
candidate pathogenic genes, is responsible for most of our
knowledge concerning IPF pathogenesis. In this context, current
research suggests that the mechanisms driving IPF reflect
abnormal, deregulated wound healing within the lung, involving
increased activity and possibly exaggerated responses by a spec-
trum of proinflammatory and profibrogenic factors [1–7].
Tumor Necrosis Factor (TNF) is a pleiotropic cytokine
expressed by many cell types in response to infection or injury.
TNF affects multiple responses that extend well beyond its well-
characterized pro-inflammatory properties to include diverse
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functions can be both beneficial, as well as detrimental.
Inappropriate production of TNF has been implicated in the
pathogenesis of a variety of human diseases, including sepsis,
cerebral malaria, diabetes, cancer, osteoporosis, allograft rejection,
multiple sclerosis, rheumatoid arthritis, and inflammatory bowel
diseases [8,9]. Increased levels of TNF have been found in IPF
patients [10–13], as well as in various animal models of PF [14–
18], while TNF polymorphisms have been associated with an
increased risk of developing the disease [19].
In order to decipher the role of TNF and TNF-mediated
inflammation in the development of PF, we have systematically
administered intravenous BLM to genetically modified mice of the
same susceptible genetic background, lacking components of TNF
signaling in the hematopoietic and/or the non-hematopoietic
cellular compartments. Transmembrane (tm) TNF expression
from non-hematopoietic cells was shown to be sufficient to elicit an
inflammatory response to BLM, while soluble (sol) TNF to be
necessary for appropriate lymphocyte recruitment, TGF-b1
expression and the development of fibrotic lesions.
RESULTS
TNF is necessary for the development of PF
To decipher the role of TNF in the development of PF we have
administered BLM to genetically modified mice (of the same
susceptible genetic background; C57/Bl6) lacking components of
TNF signaling. In order to compare multiple mouse lines,
experimental procedures were standardized as described in detail
in Figure S1. As expected, BLM administration in WT mice
resulted in progressive subpleural/peribronchial pulmonary in-
flammation, which subsequently diffused into the parenchyma
(Fig. 1A; WT). Accordingly, alveolar inflammatory cells, as
measured in bronchoalveolar lavage fluid (BALF), increased
gradually to peak 23 d post BLM injection (Fig. 1B; WT).
Inflammation was followed by the development of mainly
subpleural and peribronchial fibrotic patches, characterized by
alveolar septa thickening and focal dilation of respiratory
bronchioles and alveolar ducts (Fig. 1A; WT). Concomitantly,
collagen accumulation peaked 23 d post BLM injection, as
measured in lung protein extracts with a soluble collagen assay
(Fig. 1C; WT). In sharp contrast, BLM-injected tnf
2/2 mice were
completely protected from the development of disease, exhibiting
no inflammation, lack of collagen accumulation and normal lung
architecture (Fig. 1A,B,C; tnf
2/2). Thus, TNF expression is
necessary for collagen accumulation and the development of
BLM-induced PF.
Inflammatory responses elicited by transmembrane
TNF do not support the development of PF
TNF is initially produced as a 26 kDa transmembrane molecule
(tmTNF), later to be cleaved by TNF-a Converting Enzyme
(TACE) to release the soluble 17 kDa TNF cytokine (solTNF)
[20]. While both forms of TNF have been shown to be functionally
active, no specific role has been attributed to either one [21]. To
discriminate the form(s) of TNF necessary for the development of
PF, we administered BLM to genetically modified mice that
express only the transmembrane form [22]. Remarkably, although
tnf
tm/tm mice developed marked pulmonary inflammation, as
assessed by BALF inflammatory cell counts and histopathology
(Fig. 1A,B; tnf
tm/tm), they did not overexpress collagen and did not
develop any fibrotic lesions (Fig. 1C,A; tnf
tm/tm). To confirm the
necessity of solTNF for PF development, a single low dose
(200 ng/ml) of aerosolized recombinant human TNF (rhTNF) was
administered to tnf
tm/tm mice immediately prior to BLM injection.
Reconstituted tnf
tm/tm mice now overexpressed collagen and
developed fibrotic lesions (Fig. 2). Therefore, tmTNF-juxtacrine
induced inflammation is not sufficient to activate the fibrotic phase
of the disease, whereas additional paracrine signaling from the
soluble form of TNF is needed.
Lymphocytes are necessary for solTNF-driven PF
To analyze the TNF-induced inflammatory response, shown to be
necessary for the development of PF, the inflammatory cells in
BALF were analyzed qualitatively by cytospins. As evident from
Figure 3A, under physiological conditions (saline injection)
alveolar spaces are populated mainly by macrophages. BLM
injection results in a quantitative increase of all inflammatory cells
(see also Fig. 1), and in particular to a preferential accumulation of
lymphocytes (Fig. 3A,B and C). As expected, BALF from BLM-
injected tnf
2/2 mice, that failed to develop any inflammatory
response and subsequent fibrosis, was almost devoid of any
inflammatory cells (Fig. 1 and 3B,C). Remarkably, BALF cellular
analysis of BLM-injected tnf
tmtm mice indicated that recruitment of
lymphocytes is severely compromised (Fig. 3B), as opposed to the
minor differences observed in macrophages (Fig. 3C). Therefore, it
seems that solTNF is required for proper recruitment (and/or
expansion) of lymphocytes, which in turn are necessary for the
development of fibrosis. Indeed, nasal administration of rhTNF to
BLM-injected tnf
tmtm mice, that restores disease potential, resulted
in massive accumulation of lymphocytes (Fig. 3D). In accordance,
administration of an anti-TNF antibody to BLM-injected WT
mice resulted in attenuation of inflammatory lymphocytes (un-
published data). To prove further the absolute requirement for
lymphocytes in the development of the TNF-driven BLM/PF and
resolve the reported discrepancies [23,24], we administered BLM
to rag-1
2/2 mice (C57/Bl6) that are devoid of T and B cells [25].
Immunodeficient mice failed to develop any pathological signs,
maintaining normal lung architecture (Fig. 4).
Non-hematopoietic expression of TNF is sufficient
for BLM/PF
To identify possible cellular TNF sources in PF development, we
performed a series of bone marrow transfers into lethally
irradiated hosts, as outlined in Figure S2 and described in
Materials and Methods. Reconstituted recipient mice bearing
hematopoietic cells with the genetic background of the donor
mouse and non-hematopoietic cells with the genetic background of
the host mouse were then injected with BLM to assess disease
development. Mice that lacked TNF expression in the hemato-
poietic compartment (tnf
2/2 to WT) developed both inflammation
and fibrosis with proper lymphocyte recruitment; in contrast,
abolishing TNF expression from non-hematopoietic cells (WT to
tnf
2/2) resulted in complete disease protection (Fig. 5). Thus, these
results indicate that radio-resistant non-hematopoietic cells
constitute the main cellular source of TNF in the pathogenesis
of PF.
To confirm non-hematopoietic TNF production and to identify
TNF producing cells, paraffin-embedded lung sections from BLM
injected WT mice sacrificed 7 d post injection were immunos-
tained with an anti-TNF antibody. As shown in Figure 6A, TNF
expression was localized to the epithelial cells upon injection of
BLM. In accordance with the bone marrow transplantation
experiments, very few resident macrophages exhibited any
significant TNF staining.
BLM-induced DNA double strand breaks in epithelial cells are
considered the primary insult in the pathogenesis of BLM/PF,
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cascade [2,26]. To examine if BLM-induced TNF-expressing
epithelialcells wereundergoing apoptosis,anti-TNF-immunostained
lung sections were counterstained (TUNEL) for the simultaneous
detection of apoptotic cells (Fig. 6B). Indeed, TNF expression
colocalized with apoptosing epithelial cells, indicating an early role
for TNF production in the pathogenetic cascade.
TNF expression is necessary for TGF-b1 induction
TGF-b1, a cytokine long known for its fibrotic properties [27], has
been shown to be able to bypass the absolute requirement for TNF
signaling in the development of the disease, since TGF-b1
overexpression induces fibrogenesis in the lungs of the fibro-
genic-resistant double TNF Receptor (TNFR) deficient mice [28].
Interestingly, in our experimental model, TNF-dependent disease
resistance was always associated with diminished TGF-b1
expression (Fig. 7), indicating that TNF signals are required for
macrophage/fibroblast production of this major pro-fibrotic
cytokine.
Multiple, redundant TNFR signaling in PF
TNF exerts its effects through two distinct receptors, TNFRI (p55)
and TNFRII (p75), expressed in almost all cell types [29].
Although solTNF is regarded as the main ligand for TNFRI and
Figure 1. solTNF is necessary for BLM-induced PF
WT and transgenic mice were injected intravenously with saline or BLM and sacrificed at indicated time points post injection. (A) Representative H/E
(46) and Masson (106) stainings of lung sections of WT, tnf
2/2 and tnf
tm/tm mice. Inflammatory infiltrates are evident in WT and tnf
tm/tm lungs at
subpleural and peribronchial areas (open arrow) while fibrosis develops only in WT lungs (closed arrow). tnf
2/2 mice show no signs of disease. (B)
Total inflammatory cell counts in BALF, expressed as a percentage over the corresponding saline injections. (C) Soluble collagen determination in
lung extracts, expressed as a percentage of the corresponding saline injections. Bars represent mean values 6SD. Statistically significant differences
are indicated by the corresponding t-test p values.
doi:10.1371/journal.pone.0000108.g001
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[30], the precise role of the different TNF receptors is far from
solved. Lack of TNFRI & RII receptor signalling protects mice
from developing fibrotic lesions upon exposure to asbestos [31].
Similarly, BLM administration to C57/Bl6 mice lacking both
TNF receptors also resulted in disease protection, indicating the
absolute necessity of TNFR signalling in BLM/PF [32]. To
establish TNFR specificity and discriminate receptor usage in the
development of PF, BLM was administered to genetically modified
mice lacking either receptor (tnfRI
2/2 and tnfRII
2/2). Both mouse
lines developed both pulmonary inflammation and fibrosis with
minor differences from WT mice (Fig. 8), indicating a redundant
role of TNF receptors in the development of PF and/or the
existence of compensatory mechanisms. In agreement and
considering the pleiotropy of TNF and the central role of TNFRI
in many biological processes, TNFRI null mice have a remarkably
normal development. Similarly and in view of the TNFRII
mediated activity in vitro in the T-cell compartment, normal
development of thymocytes and lymphocytes in TNFRII null mice
was quite unexpected [29].
Given the TNFR necessity [33] and redundancy (Fig. 8) and in
order to identify the TNF responding cellular compartments, mice
lacking both TNF receptors (tnfR
2/2) were utilized as donors and/
or recipients in bone marrow transfer experiments as above
(Outlined in Fig. S2). Mice lacking TNFR signaling in either non-
hematopoietic (WT to tnfR
2/2) or hematopoietic (tnfR
2/2 to WT)
compartments were capable of eliciting an inflammatory response
to BLM (Fig. 9 A,B) composed mainly of macrophages (Fig. 9D).
However, absence of TNF receptors in either compartment
resulted in deficient lymphocyte recruitment and thus protection
from the development of fibrosis (Fig. 9A,C,E). Therefore it seems
that multiple TNF signals to different cellular compartments are
needed for the transition from the inflammatory to the fibrotic
phase of the disease.
Figure 2. solTNF administration restores disease potential in tnf
tm/tm mice
tnf
tm/tm mice received either aerosolized recombinant hTNF (200 ng/ml) or saline prior to injection with BLM. 23 days post injection, mice were
sacrificed for pathology evaluation. Parallel treatment with solTNF and BLM resulted in the development of fibrotic areas in the lungs of tnf
tm/tm mice.
(A) Representative H/E (46) and Masson (106) stainings of lung sections. (B) Total inflammatory cell counts in BALF, expressed as a percentage over
the corresponding saline injections. (C) Soluble collagen determination in lung extracts, expressed as a percentage of the corresponding saline
injections. Bars represent mean values 6SD. Statistically significant differences are indicated by the corresponding t-test p values.
doi:10.1371/journal.pone.0000108.g002
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Wound healing is a fundamental biological process crucial for
survival, which allows the ordered replacement of dead or injured
cellsandtherestorationofnormaltissuearchitecture.Tissuedamage
can result from several acute or chronic stimuli, including infections,
autoimmune reactions and mechanical injury. The repair process
involves two distinct stages: a regenerative, inflammatory phase, in
which the microenvironment attempts to replace injured cells; and
a fibrotic phase, in which connective tissue replaces normal
parenchymal tissue. However, although initially beneficial, failure
to control the healing process can lead to considerable tissue
remodeling and the formation of permanent scar tissue. IPF is
a prototype fibrotic disease involving abnormal wound healing in
response to multiple sites of ongoing alveolar epithelial injury. While
the direct involvement of fibrotic mechanisms in the pathogenesis of
IPF remains undisputed, the lack of natural history of the disease has
created significant controversy on the extent of the contribution of
inflammatory mechanisms.
TNF, the major proinflammatory cytokine, was among the first
candidate genes to be strongly associated with IPF. Although
TNF’s involvement in IPF development seems apparent [10–
19,34–36], a number of studies utilizing genetically modified
animals to overexpress and/or ablate TNF in various models of
IPF have yielded contradictory and/or inconclusive results.
However, these studies were performed in different animals with
different genetic backgrounds and ages, while the pathology was
induced with a variety of agents (asbestos, silica and BLM),
through different routes of administration (intratracheal, intrave-
nous, intraperitoneal and subcutaneous) and different dosing
[28,31,32,37–43]. To resolve discrepancies and to genetically
dissect TNF signaling in the pathogenesis of IPF, we utilized the
Figure 3. solTNF-dependent lymphocyte infiltration into the lung correlates with BLM/PF development
Qualitative assessment of the inflammatory response elicited by BLM in WT and transgenic mice, revealed after differential cell counts of
inflammatory cells in BALF. BLM preferentially induces increased infiltration of lymphocytes and subsequent fibrosis only in the presence of solTNF.
(A) Different cell populations in the lungs of WT mice expressed as a percentage of total cells. (B) Absolute lymphocyte and (C) macrophage numbers
in the lungs of WT, tnf
2/2 and tnf
tm/tm mice. (D) Absolute lymphocyte numbers in the lungs of tnf
tm/tm mice 23 days after treatment with hTNF and
BLM. Bars represent mean values 6SD. Statistically significant differences are indicated by the corresponding t-test p values.
doi:10.1371/journal.pone.0000108.g003
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human disease. BLM was injected intravenously in order to 1)
reproduce the route of administration of the only human PF with
a known etiology (i.e., associated with BLM cancer chemotherapy)
and 2) to avoid the pronounced and acute effects of the very
invasive and inflammation prone intratracheal route of adminis-
tration. All animals were inbred from the same colony of C57/Bl6
mice for over 20 generations, thus minimizing genetic background
effects and enabling direct comparisons. Inflammation and fibrosis
were assessed with histopathology, inflammatory cell counts,
soluble collagen expression and determination of cytokine levels.
Moreover, TNF producing and responding cellular compartments
were determined through a series of bone marrow transfer
experiments. All results are summarized in Table 1.
TNF was shown to be a prerequisite for the development of the
disease, and tnf
2/2 mice were completely protected from both
inflammation and fibrosis. For the first time, the necessary TNF
expression was shown to originate from the non-hematopoietic
compartment, predominately from apoptosing alveolar epithelial
cells. In agreement, TNF expression in lung biopsies of IPF human
patients was localized mainly in alveolar epithelial cells [11,12],
which, in independent studies, exhibit strong labeling of
fragmented DNA [44] and were shown to express a variety of
apoptotic proteins and markers [45,46]. Epithelial cell apoptosis is
considered as the initiating pathogenic insult of IPF [2,26] and its
inhibition abrogates the development of BLM/PF [47–49].
Moreover, alveolar epithelial apoptosis seems to be a perpetuating
event in the pathological cascade of IPF, since apoptotic epithelial
cells are detected primarily in areas immediately adjacent to
underlying foci of myofibroblasts [50], which have been found to
induce alveolar epithelial cell apoptosis in vitro [51,52]. Therefore
TNF expression could trigger not only an initial acute in-
flammatory response to tissue damage, but could provide chronic
inflammatory signals that would exceed the de-activation thresh-
olds of fibrotic mechanisms and lead to uncontrolled wound
healing.
TNF, as well as several other growth factors and cytokines, is
initially synthesized as a transmembrane molecule, later to be shed
by TACE to release the soluble cytokine [20]. Conceivably, given
the wide range of pleiotropic biological activities of TNF, surface
localization may serve to restrict activity to the local microenvi-
ronment, whereas release may lead to distal effects. tnf
tm/tm mice,
Figure 4. Immunodeficient mice are protected from BLM/PF
rag-1
2/2 (C57/Bl6) mice that are devoid of T and B cells were injected with BLM and sacrificed 23 days later for disease evaluation. Lack of
lymphocytes resulted in failure of disease induction as assessed with (A) representative H/E staining (46), (B) total inflammatory cell counts in BALF,
expressed as a percentage over the corresponding saline injections, (C) soluble collagen determination in lung extracts, expressed as a percentage of
the corresponding saline injections. Bars represent the mean values 6SD. Statistically significant differences are indicated by the corresponding t-test
p values.
doi:10.1371/journal.pone.0000108.g004
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only the transmembrane form of TNF shown to be active and
properly regulated [22,53]. Similar to tnf
2/2 mice, tnf
tm/tm mice
were resistant to fibrosis induction upon BLM injection. In
contrast, tmTNF expression was sufficient to induce inflammation,
driven predominantly from macrophages. Complementation with
aerosolized rhTNF allowed further recruitment of lymphocytes,
overexpression of TGF-b1 and overproduction of collagen. Thus,
Figure 5. Non-hematopoietic expression of TNF is sufficient for BLM/PF
Bone marrow transfer experiments (outlined in Fig. S2) reveal that proper disease development occurs when TNF is produced from radio-resistant
non-hematopoietic cells. (A) Representative H/E staining (46). (B) Total inflammatory cell counts in BALF, expressed as a percentage over the
corresponding saline injections. (C) Soluble collagen determination in lung extracts, expressed as a percentage of the corresponding saline injections.
(D,E) Absolute numbers of infiltrating macrophages and lymphocytes, respectively. Bars represent the mean values 6SD. Statistically significant
differences are indicated by the corresponding t-test p values.
doi:10.1371/journal.pone.0000108.g005
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(A) TNF is expressed from epithelial cells; Colocalization of TNF expression (in red) with an epithelial specific marker (SP C; in green) in lung sections of
WT mice 7 days postBLM injection. Controlrefers toimmunostainings withouttheprimary antibody. (B) Simultaneous detectionof TNFexpression and
apoptosis in lung sections of WT mice 7 days post BLM injection.A large numberof TUNEL
+ apoptoticalveolarepithelialcells (blue) exhibitmarked TNF
expression (in brown; indicated by solid arrow). Sections are counterstained with methyl green and photographed at a magnification of 406.
doi:10.1371/journal.pone.0000108.g006
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pathogenesis of BLM/PF. It appears that tmTNF directly or
indirectly controls recruitment of macrophages, while solTNF is
needed for lymphocyte recruitment/expansion and the transition
from the inflammatory to the fibrotic phase of the disease. In
further support of a unique role for tmTNF, it was shown to be
sufficient to drive an inflammatory reaction and to provide partial
control of Mycobacterium tuberculosis and Listeria monocytogenes
infections [22,54–56]; however, in the absence of solTNF, tmTNF
does not support the proper development of rheumatoid arthritis
and experimental autoimmune encephalomyelitis [22,53].
Disease pathogenesis in the BLM/PF model presented here was
always associated with preferential accumulation of lymphocytes
(Fig. 3A), implying participation of lymphocytes in the pathogen-
esis of PF in good agreement with a number of previous reports
[24,57–60]. In sharp contrast, it has been reported that BLM
induced PF is independent of lymphocytes, since immunodeficient
SCID mice [61] were shown not to be protected from BLM [23].
Given that SCID mice are leaky, containing a small number of
lymphocytes, and in order to resolve discrepancies, BLM was
administrated to rag-1
2/2 mice which are completely devoid of
T&B cells [25]. rag-1
2/2 immunodeficient mice were shown to be
completely protected from PF development (Fig. 4). Additional
experimentation will be required to further understand the
involvement of the acquired immune system in the pathogenesis
of BLM induced PF and human IPF. Experimental and clinical
studies suggest that a persistent imbalance in the expression of Th2
versus Th1 cytokines in the lung represents an additional possible
mechanism for the progression of pulmonary fibrosis. Although
corticosteroids and immunosuppressants failed to cure the disease,
promising results have been obtained from clinical trials with IFN-
c1b [62,63].
In addition to the well-documented capacity of TNF to activate
non-specific or innate inflammation, ample evidence indicates that
TNF may also affect the adaptive immune response. TNF has
been shown to induce thymocyte proliferation, to act as mitogen
for activated ab T cells or unstimulated cd T cells, and has been
identified as a crucial factor in the recruitment and activation of
antigen-presenting cells, thereby enhancing T cell activation in situ
[64]. On the contrary and as expected for a pleiotropic cytokine,
TNF can also mediate mature T cell-receptor-induced apoptosis
through TNFRII [65]. As shown in the present report, the
observed protection in tnf
2/2 and tnf
tm/tm mice was always
correlated with diminished lymphocyte accumulation (Fig. 3B,C).
More importantly, complementation of tnf
tm/tm mice with soluble
rhTNF that restored disease potential resulted in massive
accumulation of lymphocytes (Fig. 3D). Thus, it seems that soluble
TNF is required for appropriate lymphocyte accumulation and/or
expansion, which can in turn mediate the transition to the fibrotic
phase of the disease. In accordance, forced transgenic expression
(constitutive or inducible) of TNF from type II epithelial cells
through transgenic genetic modifications, resulted in leukocyte
infiltration with a predominance of lymphocytes. This led to
subsequent enlargement of air spaces in association with alveolar
wall thickening due to increased accumulation of collagen [41,43].
Similarly, systemic hTNF overexpression in the Tg3647 transgenic
mouse model of rheumatoid arthritis [66], results in massive
lymphocyte infiltration in the lung (unpublished data). Interest-
ingly, unlike with the epithelial-specific TNF expression, systemic,
non-epithelial overexpression of TNF results in pulmonary
pathology characterized as lymphoid interstitial pneumonitis,
exhibiting organized follicles that stained positively for both B
and T cells (unpublished data). Bone marrow transfer experiments
from tnfR
2/2 mice and vice versa indicate that lymphocyte
recruitment and disease induction requires the presence of TNF
receptors in both cellular compartments, suggesting that TNF-
mediated lymphocyte recruitment is indirect, most likely involving
non-hematopoietic cells as previously implied [67].
Absence of TNF-mediated lymphocyte recruitment (and
consequent disease induction) was always associated with lack of
TGF-b1 expression (Fig. 7). TGF-b1 is largely responsible for
fibroblast activation/differentiation, as well as collagen over-
expression [27]. Moreover, in our experimental model diminished
TGF-b1 expression correlated with diminished Tissue Inhibitor of
Metalloproteinase 1 (TIMP1) expression and MMP9/TIMP1
reversal of expression ratio, towards a non-degrading environment
(Fig. S3). TGF-b1 conditional overexpression induces fibrosis even
in the absence of inflammation and TNF expression [68]. As
shown recently, TGF-b1 induction from macrophages occurs in
a two-stage process requiring both TNF and IL-13 [69]. IL-13,
a prototype Th2 cytokine, is a major inducer of fibrosis in many
chronic infectious and autoimmune diseases [70,71], while TNF
has been shown to be a critical component of the IL-13 mediated
protective Th2 response during helminth infection [72]. There-
fore, since there is no evidence of TGF-b1 induction in the
absence of inflammation, coordinated signaling of TNF/IL-13
could control induction of this major profibrotic cytokine and the
transition to the fibrotic phase of the disease.
IPF and related pulmonary fibrotic disorders affect millions of
individuals worldwide, where the clinical outcome for the vast
majority of the patients remains poor. Administration of
corticosteroids and other general anti-inflammatory and immu-
nosuppressant drugs fails to control the disease, leading physicians
to alternate modes of treatment. Surprisingly, there have been only
a few isolated case reports in the literature accessing the efficacy of
anti-TNF treatment, perhaps due to the failure of corticosteroids
as well as to the increased risk of infections associated with current
anti-TNF biologics. Treatment with infliximab (chimeric anti-
TNF antibody) of a rheumatoid arthritis patient with progressive
pulmonary symptoms associated with radiographic fibrosis in
order to control articular symptoms resulted in sustained
improvement in dyspnea, cough and exercise tolerance in addition
Figure 7. TNF expression is required for TGF-b1 induction
TGF-b1 levels determination in BALF samples of the indicated mice with
an ELISA assay. Bars represent the mean values 6SD. Statistically
significant differences are indicated by the corresponding t-test p
values.
doi:10.1371/journal.pone.0000108.g007
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treatment of a patient with lung fibrosis and pulmonary
hypertension associated with advanced systemic sclerosis refracto-
ry to conventional therapies seemed effective, improving quality of
life [74]. Moreover, etanercept (a hybrid molecule consisting of
TNFRII linked to the Fc domain of human IgG1) administration
in nine subjects with IPF demonstrated tolerability, with functional
improvement in some [75].
Our results presented in this report reinforce the importance of
assessing the efficacy of TNF antagonists in IPF treatment. More
importantly, specific blockade of soluble TNF would be predicted
to abolish the detrimental pro-fibrotic effects of TNF, while
maintaining sufficient host defense against infections. Preliminary
results from on-going in vivo studies with an engineered dominant-
negative peptide acting as a selective inhibitor of soluble TNF [76]
indicated comparable efficacy with etanercept, which alleviated
pathological symptoms as previously reported [14,18,35]. Al-
though anti-TNF treatment is unlikely to cure the disease (as in the
case of rheumatoid arthritis and Crohn’s disease), it would still
offer symptomatic relief and quality of life improvement.
MATERIALS AND METHODS
Animals
The generation of tnf
2/2 [77], tnf
tm/tm [22], tnfRI
2/2 [78], tnfRII
2/2
[79], and rag-1
2/2 [25] mice by homologous recombination in ES
cells has been described previously. All mice strains were bred and
maintained in the C57/Bl6 background (same colony) for over 20
generations in the animal facilities of the Biomedical Sciences
Research Center ‘‘Alexander Fleming’’ under specific pathogen-free
conditions, in compliance with the Declaration of Helsinki principles.
Mice were housed at 20–22uC, 5565% humidity, and a 12 h light-
dark cycle; food and water was given ad libitum. All experimentation
was approved by an internal Institutional Review Board, as well as
by the veterinary service and fishery department of the local
governmental prefecture.
Figure 8. Redundant TNFR signaling in BLM/PF
BLM was injected in tnfRI
2/2 and tnfRII
2/2 mice and disease progression monitored at the indicated time intervals. Both mouse strains developed
inflammation and fibrosis as assessed with (A) representative H/E staining (46), (B) total inflammatory cell counts in BALF, expressed as a percentage
over the corresponding saline injections, (C) soluble collagen determination in lung extracts, expressed as a percentage of the corresponding saline
injections. Bars represent mean values 6SD. Statistically significant differences are indicated by the corresponding t-test p values.
doi:10.1371/journal.pone.0000108.g008
Soluble TNF Mediates Fibrosis
PLoS ONE | www.plosone.org 10 December 2006 | Issue 1 | e108Figure 9. Multiple cellular dependencies on TNFR signaling
Bone marrow transfer experiments (outlined in Fig. S2) reveal that proper disease development requires the presence of TNF receptors in both non-
hematopoietic and hematopoietic cellular compartments. (A) Representative H/E staining (46), (B) total inflammatory cell counts in BALF, expressed
as a percentage over the corresponding saline injections. (C) Soluble collagen determination in lung extracts, expressed as a percentage over the
corresponding saline injections. (D,E) Absolute numbers of infiltrating macrophages and lymphocytes, respectively. Bars represent the mean values
6SD. Statistically significant differences are indicated by the corresponding t-test p values.
doi:10.1371/journal.pone.0000108.g009
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PF was induced by a single tail vein injection of Bleomycin
hydrogen chloride (100 mg/kg body weight; 1/3 LD50; Nippon
Kayaku Co. Ltd., Tokyo) to 6- to 8-wk-old mice as previously
reported [80–82] and as described in detail in Figure S1. Disease
progression was monitored at 7, 15 and 23 days after Bleomycin
injection, in parallel with control littermate mice injected similarly
with saline (only at 23 d post injection). At the appropriate
endpoints mice were weighed and sacrificed; their lungs were
lavaged three times with 1.0 ml aliquots of saline (BronchoAlveo-
lar Lavage Fluid; BALF), followed by perfusion through the right
ventricle of the heart with 10 ml of PBS. The lungs were then
removed, weighed and dissected as indicated in Figure S1. Total
and differential cell counts were assessed with Trypan Blue and
May-Giemsa staining respectively; collagen levels were quantified
with the Sircol collagen assay (Biocolor Ltd., Belfast, UK)
essentially as previously reported [83] and as described in detail
in Figure S1. All values were normalized over control injections, in
order to be able to compare different mouse strains. The left lung
was divided sagittally; one half was snap-frozen in liquid N2 for
RNA extraction while the other half was used for histopathology,
where paraffin-embedded lung tissue samples were sectioned and
stained with Haematoxylin/Eosin and/or Masson trichromy (Fig.
S1).
Bone marrow transplantation
Bone marrow from 8-wk-old mutant and wild-type mice (C57/
Bl6) was obtained from femurs and tibia, essentially as previously
described [84] and as outlined in Figure S2. 10
7 bone marrow cells
in 200 ml of HBSS were injected intravenously into lethally
irradiated (980 rad) recipient mice (C57/Bl6), a dosage that never
produced any signs of inflammation or fibrosis in control animals
(as it can be seen in the control groups of Figs. 5 and 9). Mice were
maintained in isolated specific pathogen-free conditions and kept
on an antibiotic regime (neomycin sulfate 1 mg/ml) for 2 wk.
Reconstitution was assessed via specific staining for CD4/CD8,
B220 and GR-1 antigens via FACSH analysis of heparinized blood
samples (Fig S2). After durable bone marrow engraftment had
been established (8 wk), pulmonary fibrosis was induced by
administration of bleomycin. Mice were sacrificed 23 d post-
injection and lung injury was assessed as above.
Immunohistochemistry and TUNEL assay
Deparaffinized and rehydrated 5 mm-thick sections of paraffin
embedded lung tissue samples were incubated with a goat
polyclonal anti-mouse TNF Ab (R&D Systems, Minneapolis,
MN, USA) overnight at 4uC. Sections were then incubated with
0.03% H2O2 followed by anti-goat IgG-HRP (Vector Laborato-
ries, Burlingame, CA, USA) for 30 min at RT. Bound peroxidase
activity was detected by staining with diaminobenzidine (DAB,
Sigma, St Louis, MO, USA). For the simultaneous in situ detection
of apoptotic cells (TUNEL assay), sections were first processed as
above and after color development with DAB, they were
incubated with terminal deoxynucleotidyl transferase (TdT)
(Roche Diagnostics, Mannheim, Germany) at 37
oC for 1 h in
a humidified chamber. Then, according to manufacturer’s
instructions, sections were incubated with the alkaline phospha-
tase-conjugated secondary Ab and developed using the Fast Blue
kit (Vector Laboratories, Burlingame, CA, USA). Prior to
mounting, sections were counterstained with methyl green.
For the identification of TNF producing cells, lung sections
processed as above were incubated with a goat polyclonal anti-
mouse TNF Ab (R&D Systems, Minneapolis, MN, USA) for 1 h at
RT. After washing, sections were incubated with a donkey anti-
goat Alexa Fluor 555 secondary Ab (Molecular Probes/Invitrogen,
Carlsbad, CA, USA) for 30 min at RT. Sections were then
sequentially incubated with an anti- pro-SP-C Ab (Upstate,
Temecula, CA, USA) at RT for 1 h, followed by a goat anti-
rabbit Alexa Fluor 488 Ab (Molecular Probes/Invitrogen,
Carlsbad, CA, USA). Finally, sections were mounted and
photographed under a Nikon ECLIPSE E800 microscope (Nikon
Corp., Shinagawa-ku, Tokyo, Japan).
Airway challenge with rhTNF
Recombinant human TNF (hTNF; XENCOR, CA, USA) was
dissolved at a concentration of 200 ng/ml in normal saline, at
a final volume of 3 ml. The solution was administered by a custom
made nebulizer flowing at 4 L/min of O2 for 25 min into an
airtight chamber containing 5–7 mice.
ELISA
Quantification of TGF-b1 in BALF samples was performed with
the Quantikine Immunoassay, according to manufacturer’s
instructions (R&D systems, Inc, Minneapolis, MN, USA).
Statistical analysis
BALF cell counts, collagen levels and ELISA values were analyzed
for statistical significance with student’s t-test (in pairwise
comparisons), utilizing the statistical software package Sigmaplot
(Systat Software Inc, Richmond, CA, USA).
SUPPORTING INFORMATION
Figure S1 Animal model of BLM-induced Pulmonary Fibrosis.
Found at: doi:10.1371/journal.pone.0000108.s001 (0.23 MB
DOC)
Figure S2 Schematic overview of bone marrow transplantation
experiments.
Found at: doi:10.1371/journal.pone.0000108.s002 (1.62 MB TIF)
Table 1. Genetic dissection of TNF signalling in BLM/PF
......................................................................
Cellular compartment Inflammation Fibrosis
Non-hematopoietic Hematopoietic M L TGF-b1 Collagen
tnf
+/+ tnf
+/+ ++ + +
tnf
2/2 tnf
2/2 22 2 2
tnf
+/+ tnf
2/2 ++ nd +
tnf
2/2 tnf
+/+ 22 nd 2
tnf
tm/tm tnf
tm/tm + 22 2
tnf
tm/tm+solTNF tnf
tm/tm
+solTNF
++ nd +
tnfRI
2/2 tnfRI
2/2 ++ nd +
tnfRII
2/2 tnfRII
2/2 ++ nd +
tnfR
2/2 tnfR
+/+ (+) 2 nd 2
tnfR
+/+ tnfR
2/2 + 2 nd 2
rag-1
2/2 rag-1
2/2 22 nd 2
Overview and comparison of experimental findings presented in this report. M,
macrophages; L, lymphocytes; nd, not determined. +/2 denote a positive/
negative statistically significant correlation.
doi:10.1371/journal.pone.0000108.t001
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